Volume 42, Issue 4, Pages (April 2005)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
MELD: the holy grail of organ allocation?
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Stuart J. Forbes, Sanjeev Gupta, Anil Dhawan  Journal of Hepatology 
Volume 51, Issue 6, Pages (December 2009)
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 44, Issue 6, Pages (June 2006)
NS5A inhibitors in the treatment of hepatitis C
Volume 44, Issue 4, Pages (April 2006)
Keiji Hirata, Michael H. Nathanson  Gastroenterology 
Immigration and viral hepatitis
Volume 66, Issue 1, Pages 1-4 (January 2017)
Living donor liver transplantation: is the hype over?
What lessons have we learned in pediatric liver transplantation?
The place of downstaging for hepatocellular carcinoma
Hepatitis C core protein – The “core” of immune deception?
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Jay A. Graham, James V. Guarrera  Journal of Hepatology 
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Volume 49, Issue 3, Pages (September 2008)
Volume 44, Issue 4, Pages (April 2006)
Unmet clinical need in autoimmune liver diseases
Advancing hepatitis B virus entry inhibitors
Autophagy in the liver Journal of Hepatology
Volume 43, Issue 4, Pages (October 2005)
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Liver stem cells and model systems for liver repopulation
Volume 57, Issue 5, Pages (November 2012)
Volume 50, Issue 4, Pages (April 2009)
Volume 42, Issue 6, Pages (June 2005)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Paul C. Adams, James C. Barton  Journal of Hepatology 
Immigration and viral hepatitis
Volume 64, Issue 4, Pages (April 2016)
The potential of induced pluripotent stem cell derived hepatocytes
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
Global burden of alcoholic liver diseases
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
Volume 64, Issue 1, Pages (January 2016)
The use of hemospray in portal hypertensive bleeding; a case series
Volume 62, Issue 3, Pages (March 2015)
Volume 66, Issue 4, Pages (April 2017)
HCV animal models and liver disease
Liver transplantation in children
Manuel Hernández-Guerra, Anna Hadjihambi, Rajiv Jalan 
Reply to: “Flow cytometry makes all the difference”
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Donor-recipient matching: Myths and realities
Chimeric mouse model of hepatitis B virus infection
Elisabeth Eder, Thomas-Matthias Scherzer, Harald Hofer, Peter Ferenci 
MELD: the holy grail of organ allocation?
Volume 64, Issue 6, Pages (June 2016)
Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child
Presentation transcript:

Volume 42, Issue 4, Pages 604-605 (April 2005) Gap junctional intercellular communication is not needed for the anticholestatic effect of tauroursodeoxycholic acid in mouse liver  Thomas Pusl, Frank Rhode, Thomas Ott, Birgit Drabent, Klaus Willecke, Ulrich Beuers  Journal of Hepatology  Volume 42, Issue 4, Pages 604-605 (April 2005) DOI: 10.1016/j.jhep.2004.12.020 Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Effect of bile acids on bile flow in perfused livers of wild-type (WT) and Cx32-knockout mice (KO). Isolated livers were perfused in situ for 90min and bile flow measured gravimetrically in 15-min fractions. After 45min, the bile acid taurolithocholic acid (TLCA) alone or in combination with tauroursodeoxycholic acid (TUDCA) were infused for 45min at a continuous rate into the perfusion medium to reach a final concentration of 10μmol/L, respectively, in the portal vein. Bile flow measurements in the perfused livers were scaled by baseline bile flow (15–45min) in each experiment to minimize variability during comparisons. Means±SEM, n=3–4. Journal of Hepatology 2005 42, 604-605DOI: (10.1016/j.jhep.2004.12.020) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions